Last mentioned: Mar 4, 2026
Product Expansion
Expected rollout of next-generation software updates for handheld mass spectrometry devices.
Earnings Calls
Management teams from MASS and SRTA host simultaneous investor calls to discuss 2026 guidance.
SEC Filings
908 Devices and Strata Critical Medical file 8-K reports detailing Q4 and full-year 2025 financial results.
908 Devices Inc. and Strata Critical Medical reported Q4 2025 results, highlighting a strategic pivot toward decentralized diagnostics and bioprocessing efficiency. Both companies emphasized recurring revenue growth from consumables as they navigate a complex capital equipment environment.
908 Devices and Strata Critical Medical reported Q4 2025 results, highlighting a surge in demand for decentralized analytical tools and critical care monitoring. Both companies are pivoting toward high-growth biopharma applications as they enter the 2026 fiscal year.
908 Devices and Strata Critical Medical reported Q4 2025 results highlighting a strategic pivot toward high-margin consumables and expanded clinical utility. As both firms navigate the post-pandemic capital equipment landscape, their focus on point-of-need diagnostics and regenerative therapies is driving a transition toward more predictable, recurring revenue streams.